Description
Uses of Medicine:
Dasatinib is a second-generation multi-kinase inhibitor. Patients, Healthcare Professionals, or Hospitals can buy Dasatinib 20 mg/50 mg/70 mg/80 mg/100 mg/140 mg Tablets online from India through THE INDIAN PHARMA (a trusted Dasatinib Supplier, Exporter, and Contract Manufacturer in India) for the management and treatment of:- newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
- Adult patients with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.
- Adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
- pediatric patients aged 1 year and older with Ph+ CML in chronic phase.
- pediatric patients aged 1 year and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
Dasatinib 20 mg/50 mg/70 mg/80 mg/100 mg/140 mg is prescribed to treat certain types of blood cancers, specifically Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Chronic Myeloid Leukemia (CML) is a cancer where the body produces excess white blood cells (WBCs) because of a change in the Philadelphia chromosome. Acute Lymphoblastic Leukemia (ALL) is a form of blood cancer that commonly affects children, where white blood cells (WBCs), specifically lymphocytes, arise uncontrollably and live longer than they should. This therapeutic drug is used to treat newly diagnosed cases of CML in its chronic phase and Ph+ ALL in those who have not responded to any other treatments.
Dasatinib 20 mg/50 mg/70 mg/80 mg/100 mg/140 mg is a tyrosine kinase inhibitor (TKI). It is designed to work by blocking the abnormal signals in the body that cause unhealthy cells to grow and multiply. By targeting the specific genetic mutation that causes these blood cancers, this medicinal product helps resist or block the progression of the leukemia cells. This oral medicine is typically prescribed for adults and children aged 1 year and older who have been diagnosed with Ph+ CML or Ph+ ALL.
Like all therapeutic drugs, Dasatinib 20 mg/50 mg/70 mg/80 mg/100 mg/140 mg tablets may cause some side effects. Side effects of this medicine are often temporary and may go away as the body adjusts to the treatment. However, if any of these side effects stay longer or become bothersome, it is important to let your doctor know.
Before initiating this treatment, let your doctor know if you have any existing medical complications, particularly associated with liver or heart complications, chest pain, breathing difficulties, cough, or hepatitis B. This therapeutic drug may cause a serious reduction in blood cell counts, which can cause low platelet count, low white blood cell count (WBC), or low red blood cell count (RBC). It is very necessary to have regular blood tests to monitor your blood levels during treatment. Let your doctor know about all the medicines you are currently taking, including prescription drugs, over-the-counter medications, antacids, vitamins, and any herbal supplements.
Dasatinib 20 mg/50 mg/70 mg/80 mg/100 mg/140 mg is not for children under 1 year. Additionally, it must be used with caution in those who have certain health complications, such as liver disease or heart problems, and only under the supervision of a healthcare professional (HCP). Always follow your doctor’s instructions and attend regular check-ups to ensure the safe use of this medicinal product.
Dosage & Side Effects:
Dosage of Dasatinib in Adult Patients: The recommended starting dosage of Dasatinib for chronic phase CML in adults is 100 mg administered orally once daily. The recommended starting dosage of Dasatinib for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults is 140 mg administered orally once daily. Do not crush, cut, or chew; swallow the tablet whole. Tablets of Dasatinib can be taken with or without a meal, either in the morning or evening. Dosage of Dasatinib in Pediatric Patients with CML or Ph+ ALL: The recommended dose of Dasatinib should be administered orally once daily with or without food. Swallow tablets whole without crushing, cutting, or chewing. Recalculate the dose every 3 months, depending on changes in body weight, or more often if necessary.- Pediatric patients with a body weight of 10 kg to less than 20 kg: Daily dose is 40 mg.
- Pediatric patients with a body weight of 20 kg to less than 30 kg: Daily dose is 60 mg.
- Pediatric patients with a body weight of 30 kg to less than 45 kg: Daily dose is 70 mg.
- Pediatric patients with a body weight of at least 45 kg: Daily dose is 100 mg.
For pediatric patients with Ph+ ALL, start this treatment on or before day 15 of induction chemotherapy, when diagnosis is confirmed, and continue for 2 years. Tablet dosing is not for patients weighing less than 10 kg.
The most common side effects of Dasatinib 20 mg/50 mg/70 mg/80 mg/100 mg/140 mg oral tablets:
- as a single-agent are myelosuppression, fluid retention events, diarrhea, headache, skin rash, hemorrhage, dyspnea, fatigue, nausea, and musculoskeletal pain.
- in pediatric patients (along with chemotherapy) are abdominal pain, mucositis, pyrexia, diarrhea, febrile neutropenia, hypertension, nausea, vomiting, musculoskeletal pain, decreased appetite, cough, headache, peripheral neuropathy, rash, fatigue, constipation, arrhythmia, edema, infections (bacterial, viral and fungal), hypotension, hypersensitivity, dyspnea, epistaxis, and altered state of consciousness.